Introduction
Breast cancer is the most common cancer in females and the second most common cause of death in the world. Approximately three-quarters of all invasive breast tumors are estrogen receptor (ER)-and/or progesterone receptor-positive, and these patients are classified as having hormone receptorpositive (HR+) disease [1] . HR+ patients benefit from endocrine therapy (ET) such as tamoxifen as well as aromatase inhibitors (AIs) including letrozole, anastrozole, and exemestane. While AIs are only used in postmenopausal breast cancer patients, tamoxifen, a selective ER-modulating agent, is an effective treatment option for pre-and postmenopausal patients. Currently, ET is recommended to be administered for 5 years as adjuvant treatment for early breast cancer. Although both tamoxifen and AIs are well tolerated and have excellent outcomes, their side effects differ considerably. Hot flushes, vaginal discharge and bleeding, fatigue, and an increased risk of endometrial cancer and thromboembolic events are common side effects reported in patients treated with tamoxifen. AI-related toxicities mainly include musculoskeletal side effects such as arthralgia, arthritis, osteopenia, osteoporosis and osteoporosis-related fractures, hyperlipidemia, as well as coronary heart disease [2] [3] [4] [5] . The state of cognitive functions after AI use has not yet been fully established. The BIG-1-98 study demonstrated that the use of letrozole improved cognitive functions in comparison to tamoxifen [6] . However, other studies revealed that ET with tamoxifen and AIs had no detectable effects on cognitive functions in patients with breast cancer [7] . This study aimed to assess the effects of ET with tamoxifen or AIs on quality of life (QoL) and cognitive functions in patients with breast cancer.
Patients and Methods
This cross-sectional study included breast cancer patients who were treated in the Department of Medical Oncology at the Hacettepe University Institute of Oncology between June 2007 and March 2009. The demographic, clinical, and pathologic features of all patients were recorded in a Microsoft Excel 2007-based database. Educational level, income, comorbidities, and marital status of each patient were recorded in the database at the time of questionnaire completion. To evaluate the effects of ET on cognitive functions, patients enrolled in the study were categorized into 3 different groups: patients receiving tamoxifen or patients receiving AIs or patients not receiving any hormonal agents. Patients who were treated for less than 6 months with ET agents, who discontinued ET for more than 3 months, and who were older than 70 years of age were excluded. The QoL of the patients was assessed with Turkish versions of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and Short Form-12 (SF-12) questionnaires. The breast cancer follow-up form and the QoL survey forms were filled in under the supervision of 2 trained interviewers using a face-to-face interview method during routine periodic follow-up sessions for each patient. The study protocol was approved by the Ethical Committee of the Hacettepe University Faculty of Medicine before the initiation of the survey, and a written informed consent was obtained from each patient (approval no.: TBK-07/4-5; approval date: 01.03.2007). In order to calculate a social functional score (SFS), the total score that a patient got from questions 26 and 27 was divided into the total number of questions (2), and thereby a RS was calculated. The difference between the highest (4) and the lowest scores (1) belonging to the answers gave the range values (3). With these values, SFS was calculated using the following formula: SFS = (1-(RS-1)/range)×100.
Quality of Life Scales and Their Evaluation
To calculate a symptom score (SS), the total score was divided into the total number of questions (13), out of which an RS was calculated. The difference between the highest (4) and the lowest scores pertaining to the answers (1) gave the range values (3). With these values, SS was calculated according to the following formula: SS = ((RS-1)/range)×100.
To calculate a fatigue score (FAS) in the symptom scale, the total score a patient obtained from questions 10, 12, and 18 was divided into the total number of questions (3), and thereby an RS was calculated. The difference between the highest (4) and the lowest scores concerning the answers (1) gave the range values (3). With these values, an FAS was calculated using the following formula: FAS = ((RS-1)/range)×100.
In order to calculate a general health score (GSS), the total score obtained from the last 2 questions was divided into the total number of questions (2), and then an RS was calculated. Again, the difference between the highest (7) and the lowest scores (1) was calculated as a range value. With this value, a GSS was calculated using the following formula: GSS = ((RS-1)/range)×100.
SF-12
The SF-12 questionnaire comprises a subset of 12 items from which the physical and mental components of the SF-12 are constructed as unique scores. These 12 items are used to construct the physical component summary (PCS) and the mental component summary (MCS) [8] . SF-12 PCS and MCS scores were generated based on a mean of 50 and a standard deviation of 10 using population norms [9] .
Statistical Analysis
All statistical analyses were conducted using SPSS version 15.0 for Windows (SPSS Inc., Chicago, IL, USA). Patient characteristics were analyzed using the chi-square test and Student's t-test. For all evaluations, statistical significance was set at p < 0.05. this study supported that although estrogen had a neuroprotective effect, tamoxifen plays an antagonistic role both in the frontal lobes and the hippocampus. Moreover, some experimental studies suggested that tamoxifen had little or no effect on cognitive function [16, 17] . In contrast, some authors insist that the drug had detrimental effects on cognitive function due to its antiestrogenic effect [18] . The association between cognitive functions and AI use has been assessed in subgroup analyses in a number of clinical trials. In 1 of these studies, breast cancer patients receiving adjuvant letrozole for 5 years had better cognitive functions than those receiving tamoxifen [6] . The authors also evaluated cognitive functions in postmenopausal breast cancer patients during the 5th year of treatment and 1 year after the end of treatment. The results showed that cognitive functions 1 year after the cessation of adjuvant ET were better compared to those at the 5th year of treatment [19] .
It was reported from the IBIS-II study that there was no change in cognitive function with anastrozole use [20] . Memory functions were found to be impaired at 6 months with anastrozole but were similar between the 2 treatment arms at 24 months. Furthermore, the results of a substudy of the ATAC study demonstrated that the anastrozole group had worse verbal memory [21] . In another study, Bender et al. [22] evaluated the cognitive functions in patients treated with ET for at least 3 months. Memory as well as verbal and visual learning were poorer with anastrozole in comparison to tamoxifen. Those findings were consistent with the results of another study with a small sample size [23] . The mentioned studies suggest that hormonal therapies with both tamoxifen and anastrozole have negative effects on cognition.
In this study, ET with either tamoxifen or AIs was found to have no effect on cognitive function when compared to patients not receiving any ET. The outcomes of the QoL scoring including SF-12 MCS, EORTC QLQ-C30 global scores, and cognitive function scores were similar in all groups. Also, there was no difference between any of the study groups in terms of QoL scores when corrected for clinical parameters like educational level, income, chemotherapy use, and age. Similar to this study, the effect of adjuvant exemestane on cognitive function was assessed in the TEAM trial [24] . Cognitive functions were compared in 3 different groups consisting of patients receiving exemestane or tamoxifen and healthy controls. Cognitive functions were slightly better in the exemestane group than in healthy controls. However, all cognitive domains were found to be significantly worse in patients treated with tamoxifen than in those receiving exemestane and in healthy controls.
There are some limitations of this study. First of all, QoL assessment was performed in a cross-sectional design. If a comparison was to be performed using the questionnaires before and after treatment, the effects of ET on cognitive function and QoL could be more suitably identified. Another limitation was the duration of the use of ET. In this study, tional level, income, chemotherapy use, comorbidities, and disease stage. Also, SF-12 MCS, PCS, and all EORTC QoL scores including cognitive functioning were similar between pre-and postmenopausal breast cancer patients.
Discussion
ET is a standard treatment approach in HR+ breast cancer. Current guidelines recommend that all women with HR+ disease should receive at least 5 years of adjuvant ET [10] . The risk of recurrence in these patients is reduced by approximately 50% with the use of ET. It was reported recently that hormone therapy with AI alone or with sequential AI and tamoxifen in postmenopausal breast cancer patients resulted in lower recurrence rates compared to patients receiving tamoxifen alone. Despite favorable outcomes obtained with AIs, issues such as which AI is more beneficial or which scheme (upfront or sequential) is better are still unclear.
Although ET provides reduced recurrence, it may also cause undesirable effects like thrombosis, bone fractures, and endometrial carcinoma. These adverse effects are usually evaluated by physicians at the follow-up appointments. However, QoL and its subcomponents in patients receiving ET are generally underestimated. Cognitive function is one of the major components of QoL, and the effects of ET on cognitive functions and global QoL scores during or after therapy are still debated.
There are 2 different types of ER, namely ER-alpha and ER-beta, and these receptors are frequently distributed in different tissue and organs. In the brain, both receptors are expressed [11] . In preclinical studies, estradiol and related mediators were demonstrated to have a neuroprotective effect [12, 13] . Tamoxifen binds to each ER with similar affinity. However, the effects of tamoxifen on brain tissue have not been well characterized. Ernst et al. [14] suggested that tamoxifen had an effect similar to that of estrogen on the brain and that both drugs might be neuroprotective. In another study, the authors evaluated the effects of estrogen and tamoxifen on brain function and structure [15] . The results of 
